comparemela.com

Latest Breaking News On - Biotechnology trading down - Page 4 : comparemela.com

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Sold by Vanguard Capital Wealth Advisors

Vanguard Capital Wealth Advisors trimmed its position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Free Report) by 21.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,000 shares of the company’s stock after selling 16,500 shares during the quarter. Vanguard Capital Wealth Advisors’ holdings […]

Nasdaq
Jpmorgan-chase-co
Morgan-stanley
Exchange-commission
Geode-capital-management
Nautilus-biotechnology-inc
Deutsche-bank
Vanguard-capital-wealth-advisors
Nautilus-biotechnology
Free-report
Capital-wealth-advisor

Vir Biotechnology (NASDAQ:VIR) Issues Earnings Results

Vir Biotechnology (NASDAQ:VIR – Get Free Report) released its earnings results on Thursday. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.24), Briefing.com reports. The business had revenue of $3.80 million during the quarter, compared to analysts’ expectations of $22.39 million. The company’s quarterly revenue […]

Canada
United-states
America
Royal-bank
Lazard-asset-management
Financial-services-group-inc
Securities-exchange-commission
Vir-biotechnology-inc
Endurance-cayman-ltd-svf
Needham-company
Vir-biotechnology

Vir Biotechnology (VIR) Set to Announce Earnings on Thursday

Vir Biotechnology (VIR) Set to Announce Earnings on Thursday
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada
Saira-ramasastry
Securities-exchange-commission
Needham-company
Lazard-asset-management
Barclays
Royal-bank
Endurance-cayman-ltd-svf
Morgan-stanley
Financial-services-group-inc
Vir-biotechnology-inc
Vir-biotechnology-company-profile

Vir Biotechnology (NASDAQ:VIR) PT Lowered to $41.00

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price decreased by equities researchers at Barclays from $59.00 to $41.00 in a research report issued to clients and investors on Friday, FlyOnTheWall reports. Barclays‘s price target points to a potential upside of 222.83% from the company’s current price. A number of other equities research […]

Alaska
United-states
China
Canada
Needham-company
Alaska-department-of-revenue
China-universal-asset-management-co
Morgan-stanley
Vir-biotechnology-inc
Commonwealth-equity-services
Endurance-cayman-ltd-svf

Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 700 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 700 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $25.11, for a total transaction of $17,577.00. Following the completion of the transaction, the insider now owns […]

China
Needham-company
China-universal-asset-management-co
Vir-biotechnology-company-profile
Endurance-cayman-ltd-svf
Vir-biotechnology-inc
Tucker-asset-management
Nasdaq
Morgan-stanley
Securities-exchange-commission
Third-bancorp

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.